Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Blueprint Medicines Corporation

SG&A Expenses: Takeda vs. Blueprint Medicines

__timestampBlueprint Medicines CorporationTakeda Pharmaceutical Company Limited
Wednesday, January 1, 20147890000612613000000
Thursday, January 1, 201514456000650773000000
Friday, January 1, 201619218000619061000000
Sunday, January 1, 201727986000628106000000
Monday, January 1, 201847928000717599000000
Tuesday, January 1, 201996388000964737000000
Wednesday, January 1, 2020157743000875663000000
Friday, January 1, 2021195293000886361000000
Saturday, January 1, 2022237374000997309000000
Sunday, January 1, 20232951410001053819000000
Monday, January 1, 20243592720001053819000000
Loading chart...

Unleashing insights

A Tale of Two Companies: SG&A Expenses in Focus

In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Blueprint Medicines Corporation, a rising star, offer a fascinating study in contrasts. Over the past decade, Takeda's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of Blueprint Medicines, reflecting its expansive global operations. In 2023, Takeda's SG&A expenses reached a staggering 1.05 trillion yen, marking a 72% increase since 2014. Meanwhile, Blueprint Medicines, with its focused approach, saw its SG&A expenses grow by 3,640% over the same period, reaching 295 million yen in 2023. This dramatic rise underscores Blueprint's aggressive expansion and investment in innovation. The data reveals a compelling narrative of growth and strategy, highlighting the diverse paths these companies take in the ever-evolving pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025